Breaks Categories: News

TuesdayJun 30, 2026 9:30 am

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Completes Enrollment Ahead of Schedule in Heart Attack Detection Pilot Study

HeartBeam (NASDAQ: BEAT) announced it has completed patient enrollment ahead of schedule in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The study enrolled 120 patients presenting with chest pain at two clinical sites in Belgrade, Serbia, with participants evaluated using both a standard 12-lead ECG and the company's 3D ECG technology. Data analysis is underway, and HeartBeam plans to present the results at a major cardiology conference later this year. The company said the study results are expected to support discussions with the FDA on the design of a planned U.S. pivotal trial and a…

Continue Reading

TuesdayJun 30, 2026 9:10 am

NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances SPC-15 Intranasal PTSD Program With Device Robustness Study

Silo Pharma (NASDAQ: SILO), announced that drug-device development partner Resyca will conduct a robustness study of the microchip-based Soft-Mist Nasal Spray system used to deliver SPC-15, the company's lead intranasal prophylactic treatment candidate for post-traumatic stress disorder. The study will evaluate device performance consistency and the stability of SPC-15 and placebo formulations over a 30-day period, supporting the combination-a portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. The company said the study is…

Continue Reading

TuesdayJun 30, 2026 9:00 am

NetworkNewsBreaks – Globavend Holdings Limited (NASDAQ: GVH) Launches AI-Produced Micro Drama, Expands Digital Entertainment Platform

Globavend Holdings (NASDAQ: GVH) announced the debut of its first fully AI-produced original micro drama, "Buried Innocent," marking its entry into the growing global micro-drama market. Created using the company's proprietary "Imaginary" AI-powered cinematic production platform, the series showcases an end-to-end generative AI workflow designed to accelerate production, reduce costs and support multilingual global distribution. Globavend also released "Kopi-Kopi," an original live-action micro drama, with both series available through its proprietary "Loomi: Short Drama" streaming platform and on TikTok. The company said it plans to monetize its content through subscriptions, transactional video-on-demand, advertising, licensing and international distribution. Management said the…

Continue Reading

MondayJun 29, 2026 11:52 am

NetworkNewsBreaks – Suntex Enterprises Inc. (OTC: SNTX) Appoints Former SpaceX Technology Executive to Board 

Suntex Enterprises (OTC: SNTX) announced the appointment of Vincent Ornelas as an independent director, adding more than a decade of executive technology experience to its board as the company advances its long-term strategy of building a diversified operating business. Ornelas spent nearly 11 years in executive technology roles at SpaceX, supporting leadership during the company's expansion, including early Starbase development and technology infrastructure for Starlink and xAI initiatives, and currently serves as an executive support engineer at Citadel. The company said Ornelas' expertise in enterprise infrastructure, cybersecurity, artificial intelligence integration and executive technology strategy will help guide Suntex as it expands its construction, infrastructure, development and manufacturing operations. The appointment follows the company's recent efforts…

Continue Reading

MondayJun 29, 2026 11:43 am

NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Peer-Reviewed Validation of Deciparticle(TM) Platform 

Oncotelic Therapeutics (OTCQB: OTLC), together with Sapu Nano, announced the publication of a peer-reviewed manuscript in the International Journal of Molecular Sciences validating its proprietary Deciparticle(TM) nanoparticle platform through the development of Sapu003, an investigational intravenous everolimus formulation currently being evaluated in an ongoing Phase 1b clinical trial. The publication details the platform's formulation design, scalable cGMP manufacturing process, product stability and preclinical performance, while demonstrating its potential to enable intravenous delivery of poorly water-soluble therapeutic compounds. The company said the research also supports broader applications for the Deciparticle(TM) platform beyond everolimus, including additional hydrophobic drug candidates. Sapu003 is currently being evaluated in a Phase 1b dose-escalation study in patients with advanced mTOR-sensitive solid tumors…

Continue Reading

MondayJun 29, 2026 11:33 am

NetworkNewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Positioned for AI Infrastructure Growth Through TechForce Robotics

Nightfood Holdings (OTCQB: NGTF), through its TechForce Robotics subsidiary, is positioning itself to capitalize on the ongoing migration of Taiwan's semiconductor supply chain to the United States through a strategic alliance with Taiwan-based Jiun Jiang Enterprise Co. Ltd. The partnership provides TechForce Robotics with access to semiconductor-grade manufacturing expertise in advanced packaging, thermal management and industrial automation, strengthening its position in markets supporting AI infrastructure, advanced semiconductor production and next-generation manufacturing. The editorial highlights how growing U.S. semiconductor investment, led by Taiwan Semiconductor Manufacturing Company (NYSE: TSM) and supported by CHIPS Act funding, is creating demand for automation, robotics and precision manufacturing technologies. It also points to continued AI infrastructure expansion by NVIDIA (NASDAQ: NVDA), Advanced Micro Devices…

Continue Reading

MondayJun 29, 2026 10:05 am

NetworkNewsBreaks – Swarmer, Inc. (NASDAQ: SWMR) Expands European Software Contract, Adds $1.02 Million in Expected Revenue

Swarmer (NASDAQ: SWMR) announced an amendment to its May 2026 software licensing agreement that increases the total contract value to $3.87 million and is expected to generate an additional $1.02 million in revenue. Under the revised agreement, Czech-based Progress TRW S.R.O. will purchase $1.41 million in SkyKnight software licenses, while Meta Bureau LLC increased its original autonomy software order from $1.38 million to $2.47 million. If all contract options are exercised by Meta Bureau and Progress TRW, the agreement could reach a total value of $14.20 million. The licenses cover Swarmer's software platform, including its operating system, artificial intelligence and…

Continue Reading

MondayJun 29, 2026 9:40 am

NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal 2026 Results, Highlights Phase 3 Progress

This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) reported fiscal 2026 financial results and provided an update on its clinical pipeline, highlighting continued progress of its lead candidate HLP003 for major depressive disorder. The company said its Phase 3 APPROACH trial has surpassed 88% enrollment and remains on track to deliver topline data in the fourth quarter of 2026, while enrollment continues in the second pivotal Phase 3 EMBRACE study. Helus also said it expects to finalize the design of the next clinical study for HLP004…

Continue Reading

MondayJun 29, 2026 9:30 am

NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Enrolls First Patient in Phase 2 Depression Trial

Tonix Pharmaceuticals (NASDAQ: TNXP) announced the first patient has been enrolled in the HORIZON Phase 2 trial evaluating TNX-102 SL 5.6 mg as a first-line monotherapy for adults with major depressive disorder (MDD). The randomized, double-blind, placebo-controlled study is expected to enroll approximately 360 patients at about 30 U.S. sites and will assess changes in depression severity after six weeks of treatment, along with measures of sleep quality, anxiety and global clinical improvement. TNX-102 SL is designed to improve sleep quality, which the company believes plays an important role in MDD, and is already approved by the FDA under the…

Continue Reading

MondayJun 29, 2026 9:20 am

NetworkNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Launches AI Agent Platform for Patient Scheduling and Care Coordination

HealthLynked (OTCQB: HLYK) announced the launch of its next-generation AI Agent Platform, a conversational voice AI solution designed to automate patient scheduling, care coordination and healthcare communications for both patients and providers. The platform supports inbound and outbound voice interactions, enabling AI agents to schedule appointments, navigate physician office phone systems, collect patient and insurance information, perform intake functions, confirm appointments and provide 24/7 answering services for healthcare practices. The company said the platform is designed to help physician practices, accountable care organizations, health systems and insurers improve patient access while reducing administrative burdens and staffing requirements. HealthLynked plans a…

Continue Reading